At the news
? MIXEDIMPACT 6/10 8-K filed Feb 25, 2026 at 07:38 ET
Medline reported strong full-year 2025 revenue growth of 11.5% to $28.4 billion, but net income declined 3.6% to $1.2 billion due to higher costs from tariffs, headcount investments, and IPO-related expenses. Adjusted EBITDA grew 3.2% to $3.5 billion. The company completed its IPO and provided 2026 guidance for organic sales growth of 8-9% and Adjusted EBITDA of $3.5-$3.6 billion.
- Fourth quarter 2025 net sales: $7.8 billion (+14.8% YoY)
- Full year 2025 net sales: $28.4 billion (+11.5% YoY)
- Fourth quarter 2025 net income: $180 million (-37.7% YoY)
- Full year 2025 net income: $1.2 billion (-3.6% YoY)
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access